STAT
DECEMBER 22, 2023
The Food and Drug Administration issued a change to the warning label for Legend Biotech and Janssen’s myeloma CAR-T, Carvykti or cilta-cel, adding that some secondary blood cancers have occurred following treatment for multiple myeloma with the cell therapy.
pharmaphorum
SEPTEMBER 25, 2020
Furthermore, the duration of response with the PD-1 checkpoint inhibitor was nearly five times longer at 29 months versus just over six months with frontline chemotherapy.
Hospital Pharmacy Europe
DECEMBER 18, 2023
In this heterogeneous patient group, decisions on therapies and management must follow a multidimensional approach, integrating medical, socio-economic and psychological factors. Drug classes known to cause falls are commonly used in older patients , but cancer treatment can further increase this risk.
Expert insights. Personalized for you.
106 
Let's personalize your content